Sue E Bell
Overview
Explore the profile of Sue E Bell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
878
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Royle K, Gregory W, Cairns D, Bell S, Cook G, Owen R, et al.
Br J Haematol
. 2018 Jul;
182(6):816-829.
PMID: 29984830
In the Medical Research Council (MRC) Myeloma IX trial (ISRCTN684564111) patients were randomised to sodium clodronate or zoledronic acid and induction treatment: cyclophosphamide, vincristine, doxorubicin and dexamethasone (CVAD) or cyclophosphamide,...
2.
De Tute R, Rawstron A, Gregory W, Child J, Davies F, Bell S, et al.
Haematologica
. 2015 Oct;
101(2):e69-71.
PMID: 26471484
No abstract available.
3.
Rawstron A, Gregory W, De Tute R, Davies F, Bell S, Drayson M, et al.
Blood
. 2015 Feb;
125(12):1932-5.
PMID: 25645353
The detection of minimal residual disease (MRD) in myeloma using a 0.01% threshold (10(-4)) after treatment is an independent predictor of progression-free survival (PFS), but not always of overall survival...
4.
Jackson G, Morgan G, Davies F, Wu P, Gregory W, Bell S, et al.
Br J Haematol
. 2014 Mar;
166(1):109-17.
PMID: 24673708
Bisphosphonates are recommended in patients with osteolytic lesions secondary to multiple myeloma. We report on the safety of bisphosphonate therapy with long-term follow-up in the Medical Research Council Myeloma IX...
5.
Rawstron A, Child J, De Tute R, Davies F, Gregory W, Bell S, et al.
J Clin Oncol
. 2014 Jan;
32(5):476-7.
PMID: 24419132
No abstract available.
6.
Rawstron A, Child J, De Tute R, Davies F, Gregory W, Bell S, et al.
J Clin Oncol
. 2013 Jun;
31(20):2540-7.
PMID: 23733781
Purpose: To investigate the prognostic value of minimal residual disease (MRD) assessment in patients with multiple myeloma treated in the MRC (Medical Research Council) Myeloma IX trial. Patients And Methods:...
7.
Morgan G, Davies F, Gregory W, Szubert A, Bell S, Drayson M, et al.
Blood
. 2012 Apr;
119(23):5374-83.
PMID: 22498739
The Medical Research Council Myeloma IX Trial (ISRCTNG8454111) examined traditional and thalidomide-based induction and maintenance regimens and IV zoledronic acid (ZOL) and oral clodronate (CLO) in 1960 patients with newly...
8.
Morgan G, Davies F, Gregory W, Bell S, Szubert A, Navarro Coy N, et al.
Haematologica
. 2011 Nov;
97(3):442-50.
PMID: 22058209
Background: Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose therapy with autologous stem-cell transplantation. Design...
9.
Morgan G, Gregory W, Davies F, Bell S, Szubert A, Brown J, et al.
Blood
. 2011 Oct;
119(1):7-15.
PMID: 22021371
Thalidomide maintenance has the potential to modulate residual multiple myeloma (MM) after an initial response. This trial compared the effect of thalidomide maintenance and no maintenance on progression-free survival (PFS)...
10.
Morgan G, Child J, Gregory W, Szubert A, Cocks K, Bell S, et al.
Lancet Oncol
. 2011 Jul;
12(8):743-52.
PMID: 21771568
Background: Bisphosphonates are the standard of care for reducing the risk of skeletal-related events in patients with bone lesions from multiple myeloma. The MRC Myeloma IX study was designed to...